Amylyx to Unveil Phase 3 Data for Avexitide in Post-Bariatric Hypoglycemia
Event summary
- Amylyx will present topline Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia (PBH) at ObesityWeek® 2026 on November 15, 2026.
- Avexitide, a first-in-class GLP-1 receptor antagonist, showed statistically significant reductions in hypoglycemic events in prior trials.
- PBH affects ~8% of U.S. patients post-bariatric surgery, with no current FDA-approved therapies.
- Second presentation details a machine learning approach to identifying PBH patients in real-world claims data.
The big picture
Amylyx's Phase 3 data presentation marks a critical inflection point for avexitide, a first-in-class therapy targeting a high-unmet-need condition in post-bariatric patients. The absence of FDA-approved treatments for PBH creates a significant commercial opportunity, though success will hinge on regulatory efficiency and market education. The company's parallel real-world data initiative underscores the strategic importance of patient identification in rare metabolic disorders.
What we're watching
- Regulatory Pathway
- Whether avexitide's Breakthrough Therapy and Orphan Drug designations will accelerate FDA approval for PBH.
- Market Opportunity
- The pace at which Amylyx can capture the ~160,000 U.S. patients with PBH post-approval.
- Competitive Positioning
- How avexitide's GLP-1 antagonism differentiates it in a landscape dominated by GLP-1 agonists for obesity and diabetes.